Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 08.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | forth by specific reference in such a filing. Item 5.02. Departure of Directors or Certain Officers; Election of Direc |
| 25.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 10.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 13.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 03.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 05.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 03.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 03.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
Stammdaten
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Unternehmen & Branche
| Name | Xilio Therapeutics, Inc. |
|---|---|
| Ticker | XLO |
| CIK | 0001840233 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 44,4 Mio. USD |
| Beta | -0,12 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 43,766,000 | -35,036,000 | -4.19 | 154,685,000 | 35,273,000 |
| 2025-09-30 | 10-Q | 19,066,000 | -16,287,000 | -0.11 | 133,694,000 | -8,095,000 |
| 2025-06-30 | 10-Q | 8,084,000 | -15,844,000 | -0.16 | 133,813,000 | 7,069,000 |
| 2025-03-31 | 10-Q | 2,930,000 | -13,265,000 | -0.18 | 103,716,000 | 10,700,000 |
| 2024-12-31 | 10-K | 6,344,000 | -58,241,000 | -15.24 | 71,075,000 | 17,598,000 |
| 2024-09-30 | 10-Q | 2,263,000 | -14,020,000 | -0.22 | 74,658,000 | 20,974,000 |
| 2024-06-30 | 10-Q | 2,357,000 | -13,925,000 | -0.24 | 89,873,000 | 33,416,000 |
| 2024-03-31 | 10-Q | -17,203,000 | -0.62 | 82,609,000 | 25,765,000 | |
| 2023-12-31 | 10-K | -76,404,000 | -2.78 | 60,926,000 | 36,827,000 | |
| 2023-09-30 | 10-Q | -16,748,000 | -0.61 | 77,842,000 | 52,498,000 | |
| 2023-06-30 | 10-Q | -19,355,000 | -0.70 | 92,359,000 | 67,377,000 | |
| 2023-03-31 | 10-Q | -22,646,000 | -0.83 | 111,505,000 | 84,792,000 | |
| 2022-12-31 | 10-K | -88,222,000 | -3.22 | 139,165,000 | 105,647,000 | |
| 2022-09-30 | 10-Q | -19,790,000 | -0.72 | 157,414,000 | 126,298,000 | |
| 2022-06-30 | 10-Q | -24,613,000 | -0.90 | 178,127,000 | 144,217,000 | |
| 2022-03-31 | 10-Q | -21,353,000 | -0.78 | 196,352,000 | 166,121,000 | |
| 2021-12-31 | 10-K | -75,800,000 | -13.52 | 218,060,000 | 185,429,000 | |
| 2021-09-30 | 10-Q | -16,251,000 | -21.27 | 120,725,000 | -136,455,000 | |
| 2021-06-30 | 10-Q | -23,181,000 | -31.48 | -121,309,000 | ||
| 2021-03-31 | 10-Q | -16,667,000 | -23.53 | -99,135,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel | Director | Open Market Purchase | 5,000 | 8.79 | 43,950.00 | +215,4% | |
| 2026-01-02 | Brennan Kevin M. | Officer, SVP, FINANCE AND ACCOUNTING | Open Market Sale | -1,826 | 0.64 | -1,174.48 | -5,8% | |
| 2026-01-02 | Frankenfield Christopher James | Officer, Chief Financial Officer | Open Market Sale | -7,030 | 0.64 | -4,521.70 | -22,2% | |
| 2025-06-17 | Shannon James Samuel | Director | Open Market Purchase | 25,000 | 0.69 | 17,215.00 | +84,4% | |
| 2025-06-16 | Shannon James Samuel | Director | Open Market Purchase | 45,000 | 0.69 | 30,870.00 | +151,3% | |
| 2025-06-16 | Russo Rene | Director, Officer, PRESIDENT AND CEO | Open Market Purchase | 36,289 | 0.68 | 24,680.15 | +121,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.